ZNF642 Inhibitors
ZNF642 inhibitors encompass a diverse array of chemical compounds that indirectly impede the functional activities of the transcription factor ZNF642 through various cellular signaling pathways and epigenetic modifications. Compounds such as the Rho-associated protein kinase inhibitor Y-27632 and the histone deacetylase inhibitor Trichostatin A operate by restructuring the cytoskeletal dynamics and chromatin state, respectively, which are essential for the transcriptional regulation exerted by ZNF642. Inhibition of key signaling pathways by PD 98059, SB 203580, and U0126 targets the MEK/ERK and p38/MAPK pathways, leading to reduced phosphorylation of transcription factors and co-regulators that may interact with ZNF642, thereby diminishing its regulatory scope. LY 294002 and Rapamycin specifically target the PI3K/Akt and mTOR pathways, respectively, influencing the transcriptional and growth conditions that ZNF642 may be involved in, effectively decreasing its activity.
Furthermore, 5-Azacytidine and BIX01294 modulate the epigenetic landscape by altering DNA methylation and histone methylation, respectively, which can lead to a reconfigured transcriptional environment that hinders ZNF642's ability to regulate gene expression. Chetomin's interference with hypoxia-inducible factor activity and WZB117's inhibition of glucose transporter 1 (GLUT1) can also indirectly reduce the energy-dependent transcriptional activity of ZNF642. Additionally, SP600125's suppression of the JNK signaling pathway could result in a reduced transcriptional activity involving ZNF642. Collectively, these inhibitors work through distinct yet functionally convergent pathways to collectively diminish the gene regulatory functions of ZNF642.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Rho-associated protein kinase (ROCK) inhibitor Y-27632 diminishes the cytoskeletal rearrangements and transcriptional regulation mediated by ROCK. This affects the function of ZNF642 by altering the transcriptional programs it regulates within the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor PD98059 diminishes the ERK/MAPK signaling pathway. By inhibiting this pathway, the phosphorylation of transcription factors that might interact with ZNF642 is reduced, thus indirectly decreasing ZNF642’s activity in gene regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor SB203580 diminishes the p38/MAPK signaling pathway. ZNF642 is a transcription factor, and its activity can be indirectly inhibited by altering the phosphorylation status of associated proteins and transcriptional events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor LY294002 diminishes the PI3K/Akt signaling pathway. By inhibiting this pathway, the transcriptional activity of proteins that may be co-regulators of ZNF642 is altered, resulting in reduced functional activity of ZNF642. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor Rapamycin diminishes the mTOR signaling pathway. This inhibition can affect the cellular growth conditions, potentially affecting the transcriptional environment and activity of ZNF642 as it may regulate genes associated with growth. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor Trichostatin A alters chromatin structure, which can indirectly diminish the ability of ZNF642 to bind to DNA and regulate gene expression effectively. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor 5-Azacytidine alters DNA methylation status, which can affect the gene expression profile and indirectly diminish the activity of ZNF642 by altering the transcriptional landscape it acts upon. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
Histone methyltransferase G9a inhibitor BIX01294 reduces methylation on H3K9, which could indirectly diminish ZNF642 activity by altering the epigenetic marks that guide its DNA binding and gene regulatory functions. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Disruptor of hypoxia-inducible factor (HIF) Chetomin diminishes the ability of HIF to transactivate target genes, which could indirectly diminish ZNF642 activity by affecting genes that ZNF642 may co-regulate in response to hypoxia. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK1/2 inhibitor U0126 diminishes the ERK/MAPK signaling pathway. By reducing the activation of this pathway, the transcriptional regulation involving ZNF642 could be indirectly diminished as it may impact its target gene expression. | ||||||